Drugs.com - New Drug Approvals

FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections

NORTH CHICAGO, Ill., Feb. 7, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), as the first and only fixed-dose, intravenous...

Feb 10, 2025 - 02:09
 0
FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections
NORTH CHICAGO, Ill., Feb. 7, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), as the first and only fixed-dose, intravenous...
Read More

Tags:

Previous Article

Hegseth: Defense Department must return to long-term planning against strategic ...

Next Article

Luxury London Property Prices Dip While Asia Soars

Related Posts

FDA Approves Osenvelt (denosumab-bmwo), a Biosimilar to Xgeva

FDA Approves Osenvelt (denosumab-bmwo), a Biosimilar to...

Mar 5, 2025  0

FDA Approves Expanded Use of Soliris (eculizumab) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children

FDA Approves Expanded Use of Soliris (eculizumab) for P...

Mar 31, 2025  0

Spravato (esketamine) Approved in the U.S. as the First and Only Monotherapy for Adults with Treatment-Resistant Depression

Spravato (esketamine) Approved in the U.S. as the First...

Feb 9, 2025  0